- Home
- AVPT vs VRDN Comparison
AVPT vs VRDN Comparison
Compare AVPT & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVPT | VRDN |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AVPT | VRDN |
|---|---|---|
| Price | $11.83 | $33.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $18.00 | ★ $41.17 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $393,993,000.00 | $70,789,000.00 |
| Revenue This Year | $28.18 | $26,257.62 |
| Revenue Next Year | $17.77 | $4.54 |
| P/E Ratio | $1,578.01 | ★ N/A |
| Revenue Growth | 24.71 | ★ 23340.07 |
| 52 Week Low | $11.49 | $9.90 |
| 52 Week High | $20.25 | $34.29 |
Technical Indicators
Market Signals| Indicator | AVPT | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 29.77 | 61.19 |
| Support Level | $12.31 | $31.26 |
| Resistance Level | $12.96 | $34.29 |
| Average True Range (ATR) | 0.38 | 1.30 |
| MACD | -0.11 | 0.09 |
| Stochastic Oscillator | 4.59 | 84.28 |
Price Performance
Historical ComparisonAbout AVPT AvePoint Inc.
AvePoint Inc provides customizable solutions to optimize SaaS operations, enable secure collaboration, and accelerate digital transformation across technologies and industries. Its Confidence Platform delivers a comprehensive set of cloud-based solutions enabling IT operations, development operations, and cybersecurity professionals to monitor and secure the digital workplace using SaaS tools.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).